NEW HOPE IN BLADDER CANCER TREATMENT
Vessi Medical is an Israeli medical device startup that brings a new approach to treat Non-Muscle-Invasive Bladder Cancer (NMIBC). The Company uses surface cryotherapy, a treatment that utilizes extreme cold, to freeze and destroy abnormal tissue.
THE LEADING STANDARD OF CARE, TURBT, HAS NUMEROUS LIMITATIONS
Categorized as surface cancer on the inside lining of the bladder, NMIBC affects 2 million people globally with 300,000 new cases reported every year. TransUrethral Resection of Bladder Tumor (TURBT) is the leading first-line therapy. Yet, this invasive surgical procedure, performed under general anesthesia and requiring a costly hospital stay, can often be inadequate. In up to 80% of cases the cancer returns, with increased complications as patients need multiple repeat procedures that further reduce quality of life.
VESSI PROVIDES A NEW FIRST-LINE, OFFICE-BASED THERAPY ALTERNATIVE TO SURGERY
Vessis minimally invasive NMIBC solution provides a new, first-line, office-based therapy alternative to surgery. The companys patent-pending, bladder-specific cryotherapy technology eliminates costly and problematic repeat surgeries seen with TURBT. The technology successfully ablates unwanted tissue, reduces the risk of dispersed cancers cells, all while causing no bladder damage. The Vessi system consists of a standalone console and a disposable catheter that is inserted into the bladder.
CHANGING THE STANDARD OF CARE IN BLADDER CANCER
Vessi is backed by the Trendlines Group, a leading Israeli early stage investor, and led by seasoned medical device and cryotherapy veterans. The company has already demonstrated promising proof of concept in animals with its Alpha product. Vessi’s first application will initially target the $1.2 billion NMIBC market, with future applications for the treatment of overactive bladder and urinary tract infections, both billion-dollar markets.
For more information, please email eyal@vessimed.com.
